Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WAY
WAY logo

WAY Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Waystar Holding Corp (WAY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
25.420
1 Day change
2.29%
52 Week Range
42.550
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Waystar Holding Corp (WAY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's recent AI-driven innovations, strong revenue growth, and favorable analyst ratings outweigh the risks posed by insider selling and AI-related competition concerns. The current pre-market price of $24.95 presents a reasonable entry point given the company's growth potential and strategic advancements.

Technical Analysis

The MACD histogram is positive at 0.341, indicating bullish momentum, though it is contracting. RSI is neutral at 51.563, and moving averages are converging, suggesting no strong directional bias. The stock is trading near its pivot level of 24.192, with resistance at 26.574 and support at 21.809.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
7

Positive Catalysts

  • Launch of AltitudeAI™ to enhance healthcare payment efficiency, potentially unlocking billions in revenue losses.

  • AI-driven innovations projected to improve financial performance and reduce manual workflows.

  • Positive revenue growth of 24.35% YoY in Q4

  • Analysts maintain favorable ratings with multiple 'Buy' and 'Outperform' recommendations despite reduced price targets.

Neutral/Negative Catalysts

  • Insider selling increased by 280.05% over the last month.

  • Concerns over competition from AI-native competitors and execution risks in a rapidly evolving healthcare IT landscape.

  • EPS dropped by 9.09% YoY in Q4 2025.

Financial Performance

In Q4 2025, revenue increased by 24.35% YoY to $303.54M, and net income rose by 4.76% YoY to $19.99M. However, EPS dropped by 9.09% YoY to 0.1. Gross margin improved significantly by 8.31% YoY to 56.16%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts maintain a generally positive outlook with multiple 'Buy' and 'Outperform' ratings. Price targets have been lowered across the board due to peer multiple contraction and AI-related concerns, but analysts highlight the company's strong fundamentals, AI monetization potential, and favorable financial profile.

Wall Street analysts forecast WAY stock price to rise
17 Analyst Rating
Wall Street analysts forecast WAY stock price to rise
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 24.850
sliders
Low
40
Averages
47.81
High
54
Current: 24.850
sliders
Low
40
Averages
47.81
High
54
BofA
Buy
downgrade
$45 -> $38
AI Analysis
2026-04-10
Reason
BofA
Price Target
$45 -> $38
AI Analysis
2026-04-10
downgrade
Buy
Reason
BofA lowered the firm's price target on Waystar to $38 from $45 and keeps a Buy rating on the shares. The firm's Q1 survey results indicate health systems looking to make a change to their current RCM strategy was unchanged quarter-over-quarter, reports the analyst, who cites peer multiple contraction for the firm's lowered target.
Morgan Stanley
Equal Weight
initiated
$28
2026-03-30
Reason
Morgan Stanley
Price Target
$28
2026-03-30
initiated
Equal Weight
Reason
Morgan Stanley initiated coverage of Waystar with an Equal Weight rating and $28 price target. The firm believes the company \"has the pieces to win\" as AI becomes more important to revenue cycle management and that the shares look oversold. However, the \"rapidly evolving\" healthcare information technology backdrop creates execution risk amid an \"uncertain catalyst path\" for the shares, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WAY
Unlock Now

People Also Watch